Coming up to nearly 6 months since this update on closed angle...

Coming up to nearly 6 months since this update on closed angle glaucoma and whether ITrackadvance will become indicated and have an Asian monopoly of sorts, which is particularly significant for China.

https://announcements.asx.com.au/asxpdf/20231025/pdf/05wg71vjr0cqr1.pdf

They should have both peer review progress and substantially more patients having reached 12 month mark by now.

I only looked back on it as they plugged heavily the 2023 Singapore APACRS conference and the 2024 one this year is in China

https://nova-eye.com/uploads/Nova-Eye-Medical-Media-Release-APACRS-2023-8June2023.pdf

from a quick glance at the China conference not much iTrack in the program but given their study is in progress without definite outcomes maybe that’s understandable

https://apacrs2024.org

in the meantime China is not showing much progress saleswise but they are only selling old Itrack. The recent presentation states ITrackadvance approval pending so it would be good to get a timeframe.

in summary China prob a good 2 years behind US until it hits high growth for itrackadvance but when it kicks in could have an afterburner growth dividend to build off what will be then known US growth for those looking 2/3/4/5 years out.